Zim Laboratories Limited

Zim Laboratories Q3FY26 Revenue Up 12.8% to ₹1,087 Mn; PAT Turns Positive

Zim Laboratories reported Q3FY26 revenue of ₹1,087 million, up 12.8% YoY. EBITDA increased 9.1% to ₹145 million, and PAT turned positive at ₹44 million. The company plans to raise ₹35 crore via preferential allotment to Florintree Trinex LLP. Most CAPA remediation is complete, with inspections expected from March 2026.

Zim Laboratories to Incorporate Wholly-Owned Subsidiary in Chile with Investment Up to USD 15,000

Zim Laboratories Limited's Board approved the incorporation of a wholly-owned subsidiary in Chile, LATAM region. The company will invest up to USD 15,000. This move aims for business expansion in the LATAM region. Promoters will be directors on the new subsidiary's board.

Zim Laboratories Announces Q3 FY26 Results: Consolidated Profit at ₹439.76 Lakhs

Zim Laboratories reported its Q3 FY26 results. Consolidated revenue from operations was ₹10,865.93 lakhs and profit after tax was ₹439.76 lakhs for the quarter ended December 31, 2025. Standalone revenue from operations was ₹10,780.58 lakhs with profit after tax at ₹425.90 lakhs for the same period. The results were approved by the Board on February 11, 2026.

Zim Laboratories Approves Q3 FY26 Results and Chilean Subsidiary Investment

Zim Laboratories Limited approved its unaudited financial results for the quarter and nine months ended December 31, 2025. The company also approved an investment of up to USD 15,000 to establish a wholly owned subsidiary in Chile, LATAM, for business expansion.

Zim Laboratories Limited Publishes Newspaper Notice for Special Window for Re-lodgement of Transfer Requests

Zim Laboratories Limited is opening a special window for shareholders to re-lodge transfer requests for physical shares. This follows a SEBI circular and was announced via newspaper publication on February 7, 2026.

Zim Laboratories Schedules Q3 & 9MFY26 Earnings Conference Call for Feb 13

Zim Laboratories Limited will host its Q3 & 9MFY26 Earnings Conference Call on February 13, 2026, at 10:00 AM IST. The call will include the Chairman, Director (Finance), CFO, and Investor Relations. Participants can pre-register and use provided dial-in numbers.

Zim Laboratories Appoints Vikrant Bendre as President – International Business

Zim Laboratories Limited appointed Mr. Vikrant Bendre as President – International Business, effective February 2, 2026. Mr. Bendre has over 26 years of experience in international business. The company also designated Mr. Jitendra Pandey (VP – HR) and Mr. Sridhar Reddy (VP – QA) as Senior Management Personnel.

Zim Laboratories Announces EGM on Feb 16, 2026

Zim Laboratories Limited will hold an Extraordinary General Meeting (EGM) on Monday, February 16, 2026. The company has published newspaper advertisements regarding this meeting.

Zim Laboratories to hold EGM on Feb 16, 2026, for Preferential Issue

Zim Laboratories Limited will hold an EGM on February 16, 2026, to approve a preferential issue of up to 47,64,497 equity shares at ₹73.46 per share, raising approximately ₹34.99 crore from Florintree Trinex LLP. Remote e-voting is open from February 13-15, 2026.

Zim Laboratories Limited Announces Extraordinary General Meeting on February 16, 2026

Zim Laboratories Limited will hold an Extraordinary General Meeting (EGM) on February 16, 2026. The company published notices for this meeting in various newspapers on January 22, 2026, as per SEBI regulations.

Zim Laboratories to Raise ₹35 Crore Via Preferential Issue

Zim Laboratories will raise approximately ₹34.99 crore through a preferential issue of up to 47,64,497 equity shares at ₹73.46 per share to Florintree Trinex LLP. An EGM is scheduled for February 16, 2026, to seek shareholder approval for this fundraising.

Zim Laboratories amends Code of Fair Disclosure for UPSI, effective Jan 19, 2026

Zim Laboratories Limited amended its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI). The amended code is effective from January 19, 2026. The company has updated its procedures for disclosing UPSI and will host the amended code on its website. Piyush Nikhade is the designated CIRO.

Zim Laboratories Limited Complies with SEBI Depositories Regulations

Zim Laboratories Limited received a certificate from its RTA, MUFG Intime India Pvt. Ltd., confirming compliance with SEBI (Depositories and Participants) Regulations, 2018. This relates to the processing of dematerialized securities for the quarter ended December 31, 2025. The RTA confirmed timely processing and updating of the register of members.

Zim Laboratories Limited Closes Trading Window from Jan 1, 2026

Zim Laboratories Limited will close its trading window from January 1, 2026, for designated persons. The window will reopen 48 hours after the declaration of financial results for the quarter and nine months ended December 31, 2025.

Zim Laboratories Schedules Investor Meet on December 19, 2025

Zim Laboratories Limited will hold a virtual one-to-one meeting with Ageless Capital on December 19, 2025. No Unpublished Price Sensitive Information will be disclosed during the meeting. The schedule is subject to change.

ZIMLAB Announces Analyst/Investor Meet on 11 Dec 2025

Zim Laboratories Limited announced an Investors/Analysts Meet with Brescon Ventures Pvt Ltd. on 11th December, 2025. The meeting will be virtual and no UPSI will be shared.

Zim Laboratories Receives CDSCO Approval for Naproxen + Esomeprazole Capsules

Zim Laboratories received CDSCO approval for Naproxen + Esomeprazole capsules, enhancing its presence in pain management and gastro-protective areas. Commercial launch in India is expected in FY27.

ZIMLAB Releases Q2 & H1 FY26 Earnings Call Transcript, Discusses EU-GMP Remediation & H2 FY26 Outlook

ZIMLAB released its Q2 & H1 FY26 earnings call transcript, detailing improved sequential financials with ₹88.7 crore revenue and reduced loss. The company is actively addressing EU-GMP remediation by March 2026 and expects FY26 revenues to match FY25.

Zim Laboratories Limited Announces Q2 & H1 FY26 Earnings Conference Call Audio Recording

Zim Laboratories Limited has announced that the audio recording of the Q2 & H1 FY26 earnings conference call is available on the company's website.

ZIMLAB: Postal Ballot Results - Resolutions Approved

ZIMLAB announces the successful passing of special resolutions via postal ballot, including the re-appointment of Mr. Niraj Dhadiwal and Mr. Prakash Sapkal as Whole-time Directors.

Newspaper Publication: Financial Results for Quarter Ended Sep 2025

Zim Laboratories Limited has published the financial results for the quarter and half year ended 30th September 2025 in multiple newspapers on 13th November 2025. E-Auctions are scheduled on 27th, 28th & 29th November 2025.

Zim Laboratories reports H1FY26 degrowth, Q2FY26 sequential recovery, and outlines EU-GMP remediation plan

Zim Laboratories reported H1FY26 degrowth but Q2FY26 sequential recovery. A critical EU-GMP audit finding impacted commercialization, prompting a detailed remediation plan with future milestones through Q1FY27.

ZIMLAB Approves Unaudited Financial Results for Quarter and Half Year Ended September 30, 2025

Zim Laboratories Limited approved unaudited financial results for quarter and half year ended September 30, 2025. Consolidated revenue from operations stood at ₹8,871.13 lakhs.

ZIMLAB Approves Unaudited Financial Results for Quarter and Half Year Ended September 30, 2025

Zim Laboratories Limited approved unaudited financial results for Q2 and Half year ended September 30, 2025. Consolidated revenue decreased to ₹16,046.74 lakh and net loss was ₹229.95 lakh.

Zim Laboratories schedules Q2 & H1 FY226 earnings conference call on November 14, 2025

Zim Laboratories Limited will host its Q2 & H1FY26 earnings conference call on November 14, 2025, at 11:00 a.m. IST, with key management participating.

Zim Laboratories seeks shareholder approval via postal ballot for re-appointment of two Whole-time Directors

Zim Laboratories initiates postal ballot for re-appointment of Mr. Niraj Dhadiwal and Mr. Prakash Sapkal as Whole-time Directors for a two-year term starting October 1, 2025. E-voting runs from October 15 to November 13, 2025.

Compliance Certificate under SEBI Regulations 2018

Zim Laboratories Limited confirms compliance under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2025, as certified by MUFG Intime India Private Limited.

Re-appointment of Whole-Time Directors at Zim Laboratories

ZIMLAB Facility Non-Compliant with EU-GMP; CAPA Plan Required